205 related articles for article (PubMed ID: 18026137)
21. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
[TBL] [Abstract][Full Text] [Related]
22. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of indoleamine 2,3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo.
Iwamoto N; Ito H; Ando K; Ishikawa T; Hara A; Taguchi A; Saito K; Takemura M; Imawari M; Moriwaki H; Seishima M
Liver Int; 2009 Feb; 29(2):277-83. PubMed ID: 18397228
[TBL] [Abstract][Full Text] [Related]
24. Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua.
Brastianos HC; Vottero E; Patrick BO; Van Soest R; Matainaho T; Mauk AG; Andersen RJ
J Am Chem Soc; 2006 Dec; 128(50):16046-7. PubMed ID: 17165752
[TBL] [Abstract][Full Text] [Related]
25. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival.
Ino K; Yamamoto E; Shibata K; Kajiyama H; Yoshida N; Terauchi M; Nawa A; Nagasaka T; Takikawa O; Kikkawa F
Clin Cancer Res; 2008 Apr; 14(8):2310-7. PubMed ID: 18413819
[TBL] [Abstract][Full Text] [Related]
26. Interaction between LPS-induced NO production and IDO activity in mouse peritoneal cells in the presence of activated Valpha14 NKT cells.
Ohtaki H; Ito H; Ando K; Ishikawa T; Hoshi M; Tanaka R; Osawa Y; Yokochi T; Moriwaki H; Saito K; Seishima M
Biochem Biophys Res Commun; 2009 Nov; 389(2):229-34. PubMed ID: 19715679
[TBL] [Abstract][Full Text] [Related]
27. The 14kDa protein molecule isolated from garlic suppresses indoleamine 2, 3-dioxygenase metabolites in mononuclear cells in vitro.
Nikoo S; Bozorgmehr M; Namdar Ahmadabad H; Hassan ZM; Moazzeni SM; Pourpak Z; Ghazanfari T
Iran J Allergy Asthma Immunol; 2008 Dec; 7(4):203-8. PubMed ID: 19052349
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A.
Carr G; Chung MK; Mauk AG; Andersen RJ
J Med Chem; 2008 May; 51(9):2634-7. PubMed ID: 18393489
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of indoleamine 2,3 dioxygenase activity by H2O2.
Poljak A; Grant R; Austin CJ; Jamie JF; Willows RD; Takikawa O; Littlejohn TK; Truscott RJ; Walker MJ; Sachdev P; Smythe GA
Arch Biochem Biophys; 2006 Jun; 450(1):9-19. PubMed ID: 16624246
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors.
Huang Q; Zheng M; Yang S; Kuang C; Yu C; Yang Q
Eur J Med Chem; 2011 Nov; 46(11):5680-7. PubMed ID: 21925773
[TBL] [Abstract][Full Text] [Related]
31. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
32. Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.
Dolušić E; Larrieu P; Blanc S; Sapunaric F; Pouyez J; Moineaux L; Colette D; Stroobant V; Pilotte L; Colau D; Ferain T; Fraser G; Galleni M; Frère JM; Masereel B; Van den Eynde B; Wouters J; Frédérick R
Eur J Med Chem; 2011 Jul; 46(7):3058-65. PubMed ID: 21419531
[TBL] [Abstract][Full Text] [Related]
33. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.
Muller AJ; Scherle PA
Nat Rev Cancer; 2006 Aug; 6(8):613-25. PubMed ID: 16862192
[TBL] [Abstract][Full Text] [Related]
34. Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).
Dolušić E; Frédérick R
Expert Opin Ther Pat; 2013 Oct; 23(10):1367-81. PubMed ID: 23992582
[TBL] [Abstract][Full Text] [Related]
35. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.
Kumar S; Malachowski WP; DuHadaway JB; LaLonde JM; Carroll PJ; Jaller D; Metz R; Prendergast GC; Muller AJ
J Med Chem; 2008 Mar; 51(6):1706-18. PubMed ID: 18318466
[TBL] [Abstract][Full Text] [Related]
36. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
37. High-affinity uptake of kynurenine and nitric oxide-mediated inhibition of indoleamine 2,3-dioxygenase in bone marrow-derived myeloid dendritic cells.
Hara T; Ogasawara N; Akimoto H; Takikawa O; Hiramatsu R; Kawabe T; Isobe K; Nagase F
Immunol Lett; 2008 Feb; 116(1):95-102. PubMed ID: 18179826
[TBL] [Abstract][Full Text] [Related]
38. Synthetic inhibitors of the fungal detoxifying enzyme brassinin oxidase based on the phytoalexin camalexin scaffold.
Pedras MS; Minic Z; Sarma-Mamillapalle VK
J Agric Food Chem; 2009 Mar; 57(6):2429-35. PubMed ID: 19243099
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of indoleamine 2,3-dioxygenase for alloimmunity and transplantation.
Brandacher G; Margreiter R; Fuchs D
Curr Opin Organ Transplant; 2008 Feb; 13(1):10-5. PubMed ID: 18660700
[TBL] [Abstract][Full Text] [Related]
40. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
